diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5716diaendo-5716Research ArticleСтатьиArticlesЛечение сахарного диабета 2 типа сегодня. Надо ли менять приоритеты? Выводы из недавних клинических исследованийTreatment of DM2 to-day. Should we change priorities? Conclusions based on recent clinical studiesЗиловАлексей ВадимовичZilovAleksey Vadimovichazilov@hotmail.comГОУ ВПО Московская медицинская академия им И.М. Сеченова, МоскваI.M. Sechenov Moscow Medical Academy, Moscow200915122009124№4 (2009)108113Copyright © Зилов А.В., 20092009Зилов А.В.Zilov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5716

Настоящая работа посвящена анализу результатов, состоявшихся недавно клинических исследований. Отмечено, что возможное от-сутствие прочной связи между нормализацией гликемии и снижением риска развития седечно-сосудистых нарушений связано, как с от-носительно небольшой длительностью наблюдений, так и возможным влиянием ко-факторов (в том числе гипогликемия/ взаимодействиелекарственных препаратов и пр). Проанализированы работы, указывающие необходимость многофакторного подхода в лечении сахарногодиабета 2 типа, особенно в рамках снижения сердечно-сосудистой смертности или предотвращении сосудистых катастроф. Среди об-суждаемых групп препаратов, возможно влияние на риск гипогликемий или сосудистых нарушений выбраны производные сульфонил моче-вины. Проведен обзор ряда работ с применением глибенкламида, где не подтверждена возможность увеличения риска инфаркта миокардана фоне приема данного представителя ПСМ.

This work is devoted to the analysis of results of recent clinical studies. It is argued that the absence of close association between normalized glycemiaand reduced incidence of cardiovascular disorders may be due to both relatively short duration of observations and possible effect of co-factors (e.g. hypoglycemia/drug interaction, etc.). Some results suggest the necessity of multifactor approach to the treatment of DM2 especially for the reductionof cardiovascular mortality or prevention of vascular catastrophes. Sulphonylurea derivatives are regarded as putative risk factors of hypoglycemiaor vascular disorders. A number of publications are reviewed in which glibenclamide was shown to be safe in terms of risk of myocardial infarction.

сахарный диабет 2 типапроизводные сульфонил мочевины клинические рандомизированные исследованияглибеннла- мидtype 2 diabetes mellitussulphonylurea derivativesrandomized clinical studiesglibenclamideReferencesNissen S.E., Tardif J.C., Nicholls S.J. et al. Effect of torcetrapib on the progression of coronary atherosclerosis // N. Engl. J. Med. - 2007. - 356. - 1304-1316.Nissen S.E., Tardif J.C., Nicholls S.J. et al. Effect of torcetrapib on the progression of coronary atherosclerosis // N. Engl. J. Med. - 2007. - 356. - 1304-1316.Anderson G.I., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative Randomized Controlled Trial // JAMA. - 2004. - 291. - 1701-1712.Anderson G.I., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative Randomized Controlled Trial // JAMA. - 2004. - 291. - 1701-1712.Greenland P., Lloyd-Jones D. Critical lessons from ENHANCE trial. JAMA. - 2008. - 299(8). - 953-955.Greenland P., Lloyd-Jones D. Critical lessons from ENHANCE trial. JAMA. - 2008. - 299(8). - 953-955.Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes // N. Engl. J. Med. - 2007. - 356. - 2457-2471.Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes // N. Engl. J. Med. - 2007. - 356. - 2457-2471.The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events // N. Engl. J. Med. - 2008. - 358. - 1547- 1559.The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events // N. Engl. J. Med. - 2008. - 358. - 1547- 1559.The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus // N. Engl. J. Med. - 993. - 329. - 977-986 .The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus // N. Engl. J. Med. - 993. - 329. - 977-986 .United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33) // Lancet. - 1998. - 352. - 837-853.United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33) // Lancet. - 1998. - 352. - 837-853.Krolewski A.S., Warram J.H., Valsania P., Martin B.C., Laffel L.M., Christlieb A.R. Evolving natural history of coronary heart disease in diabetes mellitus // Am. J. Med. - 1991. - 90. - 56-61.Krolewski A.S., Warram J.H., Valsania P., Martin B.C., Laffel L.M., Christlieb A.R. Evolving natural history of coronary heart disease in diabetes mellitus // Am. J. Med. - 1991. - 90. - 56-61.Laakso M., Lehto S. Epidemiology of macrovascular disease in diabetes // Diabetes Rev. - 1997. - 5. - 294-315.Laakso M., Lehto S. Epidemiology of macrovascular disease in diabetes // Diabetes Rev. - 1997. - 5. - 294-315.Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein H.C., Miller M.E., Byington R.P., Goff D.C. Jr., Bigger J.T., Buse J.B., Cushman W.C., Genuth S., Ismail-Beigi F., Grimm R.H. Jr., Probstfield J.L., Simons-Morton D.G., Friedewald W.T.: Effects of intensive glucose lowering in type 2 diabetes // N. Engl. J. Med. - 2008. - 358. - 2545- 2559.Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein H.C., Miller M.E., Byington R.P., Goff D.C. Jr., Bigger J.T., Buse J.B., Cushman W.C., Genuth S., Ismail-Beigi F., Grimm R.H. Jr., Probstfield J.L., Simons-Morton D.G., Friedewald W.T.: Effects of intensive glucose lowering in type 2 diabetes // N. Engl. J. Med. - 2008. - 358. - 2545- 2559.ADVANCE Collaborative Group, Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., Marre M, Cooper M., Glas-ziou P., Grobbee D., Hamet P., Harrap S., Heller S., Liu L., Mancia G., Mogensen C.E., Pan C., Poulter N., Rodgers A., Williams B., Bompoint S., de Galan B.E., Joshi R., Travert F.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. - 2008. - 358. - 2560-2572.ADVANCE Collaborative Group, Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., Marre M, Cooper M., Glas-ziou P., Grobbee D., Hamet P., Harrap S., Heller S., Liu L., Mancia G., Mogensen C.E., Pan C., Poulter N., Rodgers A., Williams B., Bompoint S., de Galan B.E., Joshi R., Travert F.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. - 2008. - 358. - 2560-2572.Skyler S., Bergenstal R., Bonow R. et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials //Diabetes Care. - 2009. - 32(1). - 187-192.Skyler S., Bergenstal R., Bonow R. et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials //Diabetes Care. - 2009. - 32(1). - 187-192.hppt://www.americangeriatrics.org.hppt://www.americangeriatrics.org.Gaede P. Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes // N. Engl. J. Med. - 2008. - 358. - P.580-591.Gaede P. Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes // N. Engl. J. Med. - 2008. - 358. - P.580-591.hppt://www.dtu.ox.ac.uk.hppt://www.dtu.ox.ac.uk.Nathan D., Buse J.B., Davidson M.B. et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy // Diabetes Care. - 2006. - 29(8). - P. 1963-1972.Nathan D., Buse J.B., Davidson M.B. et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy // Diabetes Care. - 2006. - 29(8). - P. 1963-1972.Kahn S.E. et al. For the ADOPT stydy group: Glycemic Durability of rosiglitazone, Metformin or Glyburide / N. Engl. J. Med. - 2006. - 355. - P. 2427-2443.Kahn S.E. et al. For the ADOPT stydy group: Glycemic Durability of rosiglitazone, Metformin or Glyburide / N. Engl. J. Med. - 2006. - 355. - P. 2427-2443.Miller D.R. and Podach L. Longiditual Approaches to Evaluate Health Care Quality and Outcomes: The veterans Health Administration Diabetes Epidemiology Cohorts.//Diabetes Sci Technol . - 2008. - 2 (1). - P. 24-32Miller D.R. and Podach L. Longiditual Approaches to Evaluate Health Care Quality and Outcomes: The veterans Health Administration Diabetes Epidemiology Cohorts.//Diabetes Sci Technol . - 2008. - 2 (1). - P. 24-32

The authors declare that there are no conflicts of interest present.